Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan D Glass

Showing results (131-140 of 178) with videos related to

Pageof 18
Sort By:
The Lancet. Neurology|July 26, 2024
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose studyLeonard H van den Berg, Jeffrey D Rothstein, Pamela J Shaw, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 5, 2016
Defining SOD1 ALS natural history to guide therapeutic clinical trial designTaha Bali, Wade Self, Jingxia Liu, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|May 28, 2018
Implementing Motor Unit Number Index (MUNIX) in a large clinical trial: Real world experience from 27 centresChristoph Neuwirth, Nathalie Braun, Kristl G Claeys, et al.
Cell|August 27, 2025
Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALSZachary T McEachin, Mingee Chung, Sabrina A Stratton, et al.
Neurobiology of Aging|July 24, 2018
ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase functionMartina de Majo, Simon D Topp, Bradley N Smith, et al.
Annals of Neurology|January 3, 2021
The Effect of SMN Gene Dosage on ALS Risk and Disease SeverityMatthieu Moisse, Ramona A J Zwamborn, Joke van Vugt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 13, 2025
Oligogenic structure of amyotrophic lateral sclerosis has genetic testing, counselling and therapeutic implicationsAlfredo Iacoangeli, Allison A Dilliott, Ahmad Al Khleifat, et al.
Neuron|May 7, 2020
Chimeric Peptide Species Contribute to Divergent Dipeptide Repeat Pathology in c9ALS/FTD and SCA36Zachary T McEachin, Tania F Gendron, Nisha Raj, et al.
Frontiers in Cellular Neuroscience|March 20, 2023
Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survivalBrett N Adey, Johnathan Cooper-Knock, Ahmad Al Khleifat, et al.
Brain : a Journal of Neurology|April 12, 2023
Genetic variability in sporadic amyotrophic lateral sclerosisSien Hilde Van Daele, Matthieu Moisse, Joke J F A van Vugt, et al.
Pageof 18

Showing results (131-140 of 178) with videos related to

Sort By:
Pageof 18
The Lancet. Neurology|July 26, 2024
Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose studyLeonard H van den Berg, Jeffrey D Rothstein, Pamela J Shaw, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 5, 2016
Defining SOD1 ALS natural history to guide therapeutic clinical trial designTaha Bali, Wade Self, Jingxia Liu, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|May 28, 2018
Implementing Motor Unit Number Index (MUNIX) in a large clinical trial: Real world experience from 27 centresChristoph Neuwirth, Nathalie Braun, Kristl G Claeys, et al.
Cell|August 27, 2025
Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALSZachary T McEachin, Mingee Chung, Sabrina A Stratton, et al.
Neurobiology of Aging|July 24, 2018
ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase functionMartina de Majo, Simon D Topp, Bradley N Smith, et al.
Annals of Neurology|January 3, 2021
The Effect of SMN Gene Dosage on ALS Risk and Disease SeverityMatthieu Moisse, Ramona A J Zwamborn, Joke van Vugt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 13, 2025
Oligogenic structure of amyotrophic lateral sclerosis has genetic testing, counselling and therapeutic implicationsAlfredo Iacoangeli, Allison A Dilliott, Ahmad Al Khleifat, et al.
Neuron|May 7, 2020
Chimeric Peptide Species Contribute to Divergent Dipeptide Repeat Pathology in c9ALS/FTD and SCA36Zachary T McEachin, Tania F Gendron, Nisha Raj, et al.
Frontiers in Cellular Neuroscience|March 20, 2023
Large-scale analyses of CAV1 and CAV2 suggest their expression is higher in post-mortem ALS brain tissue and affects survivalBrett N Adey, Johnathan Cooper-Knock, Ahmad Al Khleifat, et al.
Brain : a Journal of Neurology|April 12, 2023
Genetic variability in sporadic amyotrophic lateral sclerosisSien Hilde Van Daele, Matthieu Moisse, Joke J F A van Vugt, et al.
Pageof 18